Sunshine Biopharma, Inc. (SBFM)

0.9500 +0.1426 (+17.66%) At close: 04:00PM EDT

Sunshine Biopharma, Inc.

1177 Avenue of the Americas
5th floor
New York, NY 10036
United States
332 216 1147
https://sunshinebiopharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 44

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Camille Sebaaly	CFO & Secretary	695k	N/A	1959
Dr. Abderrazzak Merzouki	Chief Science Officer & Director	340k	N/A	1964
Dr. Steve N. Slilaty Ph.D.	CEO, President & Chairman	430k	N/A	1952
Mr. Marc Beaudoin	Chief Operating Officer	N/A	N/A	1967
Mr. Malek Chamoun	Chief Development Officer	N/A	N/A	1985
Mr. Robert G. Ferreira	President of Sunshine Bio Investments Inc	N/A	N/A	1962

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.

Corporate Governance

Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.